Translational medicine as a new clinical tool and application which improves metabolic diseases: perspectives from 2012 Sino-American symposium on clinical and translational medicine

• Published in: Clinical and translational medicine 2014-02, Vol.3 (1), p.1-6
• Main Authors: Shi, Lin, López Villar, Elena, Chen, Chengshui
• Format: Article
• Language: English
• Subjects: Clinical translational medicine; Colorectal cancer; Hepatotoxicity; Medicine; Medicine & Public Health; Metabolic diseases; microRNAs; Obesity; Review; Type 2 diabetes mellitus
• ISSN: 2001-1326; 2001-1326
• DOI: 10.1186/2001-1326-3-2

Because of the economic growth and changes in lifestyle, metabolic diseases have become a major public health problem, which impose heavy economic burdens on individuals, families and health systems. However, its precise mediators and mechanisms remain to be fully understood. Clinical translational medicine (CTM) is an emerging area comprising multidisciplinary research from basic science to medical applications and as a new tool to improve human health by reducing disease incidence, morbidity and mortality. It can bridge knowledge of metabolic diseases processes, gained by in vitro and experimental animal models, with the disease pathways found in humans, further to identify their susceptibility genes and enable patients to achieve personalized medicament treatment. Thus, we have the reasons to believe that CTM will play even more roles in the development of new diagnostics, therapies, healthcare, and policies and the Sino-American Symposium on Clinical and Translational Medicine (SAS-CTM) will become a more and more important platform for exchanging ideas on clinical and translational research and entails a close collaboration among hospital, academia and industry.